BCD-201 is a monoclonal antibody being developed as a biosimilar to Keytruda® (international nonproprietary name: pembrolizumab).
A monoclonal antibody is a protein created by scientists in a laboratory, similar to the natural antibodies of the immune system, designed to bind to a specific target in the human body1.
BCD-201 is one of the drugs in BIOCAD’s clinical development program.
Weiner LM, Surana R., Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Reviews Immunology. 2010;10(5):317–27.
This section of the website contains information about an unauthorized investigational medicinal product for medical use.